Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Diabetes Mellitus, Normal Glucose Metabolism, Hyperlipidemia
Interventions: fasting 12+ hours, Non-fasting; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
Interventions: High Dose Radiation (HDR) Brachytherapy, MRI, CT, PET Scan; Radiation · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bloodstream Infection
Interventions: Accelerate PhenoTest™ BC kit, Standard of Care; Diagnostic Test
Lead sponsor: Accelerate Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Cefprozil for oral suspension 250 mg/5 mL, CEFZIL® for Oral Suspension 250 mg/5mL; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Conditions: COVID-19
Interventions: Facilitated Self-Sampling Intervention (FSSI), Testing Navigation Intervention (TNI)., Control; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 1,232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Brownsville, Texas • Houston, Texas • Tyler, Texas

Conditions: COVID-19
Interventions: IMPROVE; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 1,277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Syphilis
Interventions: Abbott Laboratories Determine test for syphilis, Investigational syphilis immunochromatographic strip test; Device
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 2 more

Conditions: Short Term Treatment of Insomnia
Interventions: Zaleplon; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza-Like Illness, Influenza
Interventions: Core Lab Test, ED Point of Care Test; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Angina, Unstable
Interventions: Point of Care cTnL testing; Diagnostic Test
Lead sponsor: University of Cincinnati; Other
Eligibility: 21 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 4
States / cities: Stanford, California • Royal Oak, Michigan • Cincinnati, Ohio + 1 more

Conditions: Healthy
Interventions: Lamotrigine; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 41 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cytomegalovirus Infections
Interventions: Valganciclovir, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 30 Days
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 21
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 18 more

Conditions: Healthy Volunteers
Interventions: Evacetrapib, High-fat Meal; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Sprains and Strains
Interventions: Passive Positioning, High-Velocity, Low-Amplitude Stretch, Slow, Mobilization Stretch; Other
Lead sponsor: University of the Pacific; Other
Eligibility: 16 Years to 60 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Stockton, California

Conditions: Syphilis Infection
Interventions: Rapid Syphilis Test; Diagnostic Test
Lead sponsor: Queen's Medical Center; Other
Eligibility: 14 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 12
States / cities: Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more

Conditions: Epilepsy, Seizure Disorder, Neurologic Disorder, Rare Diseases
Interventions: Clinical care and quality improvement; Other
Lead sponsor: Epilepsy Foundation of America; Other
Eligibility: Not listed
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2099
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Diabetes Mellitus
Interventions: Aliskiren + Valsartan; Drug
Lead sponsor: HeartDrug Research LLC; Other
Eligibility: 21 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postural Tachycardia Syndrome
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Bladder Cancer, Metastatic Transitional Cell Carcinoma
Interventions: Everolimus; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Type1diabetes
Interventions: Regular insulin (Humulin-R), intranasal route, SipNose intranasal device; Drug · Device
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Sclerosis
Interventions: High Intensity Interval Gait training, Moderate Intensity Interval gait training; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes, Diabetic Macular Edema, Diabetic Retinopathy
Interventions: OCT imaging; Device
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Wellfleet, Massachusetts • Syracuse, New York + 1 more

Conditions: Healthy
Interventions: Glimepiride Tablets 1 mg, Amaryl® Tablets 1 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fargo, North Dakota

Search by objective public record fields.

Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients

A Study of Patients Receiving High-Dose Rate Brachytherapy

Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures

Cefprozil for Oral Suspension 250 mg/5 mL, Fasting

Examining How a Facilitated Self-Sampling Intervention and Testing Navigation Intervention Influences COVID-19 Testing

COVID-19 Self-testing IMPROVE

Multi-site Study of Rapid Diagnostic Syphilis Assays

Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions

Impact of Rapid Flu Testing in BMC ED

Diagnosis and Treatment of ACS in the ED: The Impact of Rapid Bedside cTnI Testing on Outcomes

Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting Condition

Valganciclovir in Congenital CMV Infants

Study of Food on Evacetrapib (LY2484595) in Healthy Participants

Ankle Manual Therapy for Ankle Sprains

Feasibility and Acceptability of Point of Care Rapid Syphilis Testing Among Patients Seeking Family Planning Services in Hawai'i

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Epilepsy Learning Healthcare System (ELHS)

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

High Intensity Interval Gait Training in Multiple Sclerosis

OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits

Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg